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Scavenger receptor class B member 2 (SCARB2) (also 
called LIMP-2, CD36L2 or LGP85) is a major ly-
sosomal membrane glycoprotein involved in en-
dosomal and lysosomal biogenesis and maintenance. 
SCARB2 acts as a receptor for the lysosomal mannose
-6-phosphate independent targeting of β-glucuronidase 
and enterovirus 71 and influences Parkinson’s disease 
and epilepsy. Genetic deficiency of this protein causes 
deafness and peripheral neuropathy in mice as well as 
myoclonic epilepsy and nephrotic syndrome in hu-
mans. Comparative SCARB2 amino acid sequences 
and structures and SCARB2 gene locations were exam-
ined using data from several vertebrate genome pro-
jects. Vertebrate SCARB2 sequences shared 43-100% 
identity as compared with 30-36% sequence identities 
with other CD36-like superfamily members, SCARB1 
and CD36. At least 10 N-glycosylation sites were con-
served among most vertebrate SCARB2 proteins ex-
amined. Sequence alignments, key amino acid residues 
and conserved predicted secondary structures were 
examined, including cytoplasmic, transmembrane and 
external lysosomal membrane sequences: cysteine di-
sulfide residues, thrombospondin (THP1) binding sites 
and 16 proline and 20 glycine conserved residues, 
which may contribute to short loop formation within 
the exomembrane SCARB2 sequences. Vertebrate 
SCARB2 genes contained 12 coding exons. The human 
SCARB2 gene contained a CpG island (CpG100), ten 
microRNA-binding sites and several transcription fac-
tor binding sites (including PPARA) which may con-
tribute to a higher level (2.4 times average) of gene 
expression. Phylogenetic analyses examined the rela-
tionships and potential evolutionary origins of the ver-
tebrate SCARB2 gene with vertebrate SCARB1 and 
CD36 genes. These suggested that SCARB2 originated 
from duplications of the CD36 gene in an ancestral 
genome forming three vertebrate CD36 gene family 
members: SCARB1, SCARB2 and CD36.  
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Introduction 
 
Scavenger receptor class B member 2 (SCARB2) [also 
called SRB2, lysosomal membrane glycoprotein 2 
(LIMP-2), cluster of differentiation 36 like-2  
(CD36L2) or lysosomal glycoprotein 85 (LGP85)] is 
one of at least three members of the collagen type 1 
receptor (thrombospondin) CD36-like family that is an 
integrated lysosomal and endosomal membrane protein 
of many tissues and cells of the body (Calvo et al. 
1995, Fujita et al. 1992, Ogata et al. 1994, Tabuchi et 
al. 1997). SCARB2 plays a major role in lysosomal 
and endosomal membrane organization (Gamp et al. 
2003, Kuronita et al. 2002), cytosolic protein turnover 
(Roszek & Gniot-Szulzycka 2005), phagosomal traf-
ficking and macrophage activation (Carrasco-Marin et 
al. 2011). SCARB2 also serves as a lysosomal mem-
brane surface receptor of thrombospondins and other 
lipids (Tserentsoodol et al. 2006), mannose-6-
phosphate independent targeting of β-glucuronidase 
(Blanz et al. 2010, Reczek et al. 2007, Sleat et al. 
2006, Velayti et al. 2011) and enterovirus 71 (involved 
in the pathogenesis of hand, foot and mouth disease) 
(HFMD) (Lin et al. 2012, Yamayoshi et al. 2009, Ya-
mayoshi & Koike 2011). In addition to HFMD, 
SCARB2 has been implicated in diseases such as car-
diac myocyte hypertrophy (Schroen et al. 2007) and 
progressive myoclonus epilepsy and renal failure syn-
drome (Berkovic et al. 2008, Chaves et al. 2011, 
Hopfner et al. 2011, Rubboli et al. 2011) and has been 
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recognized as a candidate gene for autism (Ilu et al. 
2010) and Parkinson’s disease (Do et al. 2011, Miche-
lakakis et al. 2012). 
SCARB1 (also called CLA1, SRB1 and 
CD36L1) is a second member of the CD36 family that 
serves as a homo-oligomeric plasma membrane cell 
surface glycoprotein receptor for high density lipopro-
tein cholesterol (HDL), other phospholipid ligands and 
chylomicron remnants (Acton et al. 1996, Bultel-
Brienne et al. 2002, Connelly et al. 2004, Holmes and 
Cox 2012, Kent & Stylianou 2011, Marsche et al. 
2003). A third member of the CD36 family, CD36 
(also called SCARB3, fatty acyltranslocase [FAT] and 
glycoprotein 88 [GP88]) is an integral membrane pro-
tein of many tissues of the body which plays a role in 
fatty acyl translocation and as a multiple ligand cell 
surface receptor of oxidized low density lipoprotein 
cholesterol (LDL) (Martin et al. 2007, Tandon et al. 
1989), and has been implicated in several diseases in-
cluding insulin resistance, diabetes, atherosclerosis and 
malaria (Adachi & Tsujimoto 2006, Collot-Teixeira et 
al. 2007, Gautum & Banerjee 2011, Martin et al. 2007, 
Ren 2012, Simantov & Silverstein 2003). 
 The gene encoding human SCARB2 
(SCARB2) is on chromosome 4, encoded by 12 coding 
exons (Calvo et al. 1995) and localized between the 
genes encoding nucleoporin (NUP54) and protein fam-
ily 47 (FAM47E) (Kent et al. 2003). In addition, 
SCARB2 has been assigned to chromosome 8 in pigs 
(Kim et al. 2006) and to chromosome 5 in mice, but 
designated as Scarb2 in the latter genome (Tabuchi et 
al. 1997). SCARB2 is ubiquitously expressed in vari-
ous cells and tissues of the body, including kidney 
glomerular tubules (Berkovic et al. 2008, Desmond et 
al. 2011), liver (Tabuchi et al. 1997, Zhang et al. 
2007), retinal ganglia and photoreceptor outer seg-
ments (Tserentsoodol et al. 2006), ureter epithelial 
cells (Gamp et al. 2003), metastatic pancreas islet cells 
(Fujita et al. 1992), the cardiac intercalated disc 
(Schroen et al. 2007) and phagocytes (Carrasco-Marin 
et al. 2011). Studies of Scarb2¯/Scarb2¯ knock out 
mice have shown that SCARB2-deficiency causes 
ureteric pelvic junction obstruction, deafness and pe-
ripheral neuropathy (Gamp et al. 2003), renal tubular 
proteinuria (Desmond et al. 2011), an inability to 
mount a hypertrophic response to increased blood 
pressure, due to the absence of SCARB2 in the cardiac 
intercalated disc (Schroen et al. 2007) and macrophage
-related defects in immunity to infection (Carrasco-
Marin et al. 2011). Human clinical studies have also 
examined SCARB2 polymorphisms associated with 
diseases causing mutations of β-glucocerebrosidase 
binding, which is defective in Gaucher disease (Blanz 
et al. 2010, Velayati et al. 2011); and collapsing focal 
and segmental glomerular sclerosis (FSGS) and myo-
clonic epilepsy (Balreira et al. 2008, Berkovic et al. 
2008, Chaves et al. 2011, Desmond et al. 2011, Dib-
bens et al. 2011, Hopfner et al. 2011, Rubboli et al. 
2011). 
 This paper reports the predicted gene struc-
tures and amino acid sequences for several vertebrate 
SCARB2 genes and proteins, the secondary structures 
for vertebrate SCARB2 proteins, several potential sites 
for regulating human SCARB2 gene expression and the 
structural, phylogenetic and evolutionary relationships 
for these genes and enzymes with those for vertebrate 
SCARB2, SCARB1 and CD36 gene families. 
 
Materials and Methods 
 
Vertebrate SCARB2 gene and protein identification 
BLAST (Basic Local Alignment Search Tool) studies 
were undertaken using web tools from the National 
Center for Biotechnology Information (NCBI) (http://
blast.ncbi.nlm.nih.gov/Blast.cgi) (Altschul et al. 1997).  
Protein BLAST analyses used human and mouse 
SCARB2 amino acid sequences previously described 
(Fujita et al. 1992, Ogata et al. 1994, Calvo et al. 
1995, Tabuchi et al. 1997) (Table 1). Non-redundant 
protein sequence databases for several vertebrate ge-
nomes were examined using the blastp algorithm from 
sources previously described (Holmes 2012). This pro-
cedure produced multiple BLAST ‘hits’ for each of the 
protein databases which were individually examined 
and retained in FASTA format, and a record kept of 
the sequences for predicted mRNAs and encoded 
SCARB2-like proteins. Predicted SCARB2-like pro-
tein sequences were obtained in each case and sub-
jected to analyses of predicted protein and gene struc-
tures. 
BLAT (Blast-like Alignment Tool) analyses 
were subsequently undertaken for each of the predicted 
SCARB2 amino acid sequences using the UC Santa 
Cruz Genome Browser (Kent et al. 2003) with the de-
fault settings to obtain the predicted locations for each 
of the vertebrate SCARB2 genes, including predicted 
exon boundary locations and gene sizes. BLAT analy-
ses were similarly undertaken for vertebrate SCARB1 
and CD36 genes using previously reported sequences 
in each case (see Table 1; Holmes & Cox 2012).  
Structures for human SCARB2, mouse Scarb2 and rat 
Scarb2 transcripts were obtained using the AceView 
website to examine predicted gene and protein struc-
tures (Thierry-Mieg & Thierry-Mieg 2006). Predic-
tions for human, mouse and rat SCARB2 CpG islands, 
miRNA binding sites and transcription factor binding 
sites were obtained using the UC Santa Cruz Genome 
Browser (Kent et al. 2003). 
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Predicted Structures and Properties of Vertebrate 
SCARB2 and other CD36-like Proteins  
Predicted secondary structures for vertebrate SCARB2 
proteins, human SCARB1 and CD36, lancelet 
(Branchiostoma floridae) CD36, sea squirt (Ciona in-
testinalis) CD36 and a fruit fly (Drosophila 
melanogaster) epithelial membrane protein 
(FBpp0072309) were obtained using the PSIPRED 
v2.5 web site tools provided by Brunel University 
(McGuffin et al. 2000). Molecular weights, N-
glycosylation sites (Gupta & Brunak 2002) and pre-
dicted transmembrane, cytosolic and exocellular se-
quences for vertebrate SCARB2 proteins were ob-
tained using Expasy web tools (http://au.expasy.org/
tools/pi_tool.html). 
 
Comparative Human SCARB2 and Mouse Scarb2 
Gene Expression 
The genome browser (http://genome.ucsc.edu) (Kent et 
al. 2003) was used to examine GNF Expression Atlas 
2 data using various expression chips for human 
SCARB2 and mouse Scarb2 genes, respectively (Su et 
al. 2004) (http://biogps.gnf.org). Gene array expression 
‘heat maps’ were examined for comparative gene ex-
pression levels among human and mouse tissues show-
ing high (red), intermediate (black), and low (green) 
expression levels. 
 
Phylogeny Studies and Sequence Divergence 
Alignments of vertebrate SCARB2, SCARB1 and 
CD36 sequences were assembled using BioEdit v.5.0.1 
using the default settings (Hall 1999). Alignment of 
ambiguous regions, including the amino and carboxyl 
termini, were excluded prior to phylogenetic analysis, 
yielding alignments of 431 residues for comparisons of 
vertebrate SCARB2 sequences with human, mouse, 
chicken and zebra-fish SCARB1 and CD36 sequences 
with the lancelet (Branchiostoma floridae) CD36 se-
quence (Table 1). Evolutionary distances and phyloge-
netic trees were calculated as previously described 
(Holmes 2012). Tree topology was reexamined by the 
boot-strap method (100 bootstraps were applied) of 
resampling and only values that were highly signifi-
cant (≥95) are shown (Felsenstein 1985).   
 
Results and Discussion 
 
Alignments of Vertebrate SCARB2 Amino Acid 
Sequences 
The deduced amino acid sequences for cow (Co) (Bos 
taurus), chicken (Ch) (Gallus gallus), lizard (Li) 
(Anolis carolensis), frog (Fr) (Xenopus tropicalis) and 
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Figure 1. Amino Acid Sequence Alignments for Vertebrate SCARB2 Sequences. See Table 1 for sources of SCARB2 se-
quences; * shows identical residues for SCARB2 subunits; : similar alternate residues; . dissimilar alternate residues; predicted 
cytoplasmic residues are shown in red; predicted transmembrane residues are shown in blue; N-glycosylated and potential N-
glycosylated Asn sites are highlighted in green; predicted disulfide bond Cys residues are highlighted in cyan blue; predicted α-
helices for vertebrate SCARB2 are highlighted in yellow and numbered in sequence from the start of the predicted exoplasmic 
domain; predicted β-sheets are highlighted in grey and also numbered in sequence; bold underlined font shows residues corre-
sponding to known or predicted exon start sites; exon numbers refer to human SCARB2 gene exons; exolysosomic refers to the 
predicted SCARB2 sequence external to the lysosomal membrane. 
zebrafish (Zf) (Danio rerio) SCARB2 are shown in 
Figure 1 together with the previously reported se-
quences for human (Hu) and mouse (Mo) SCARB2 
(Table 1) (Fujita et al. 1992, Tabuchi et al. 1997).   
Alignments of human with other vertebrate SCARB2 
sequences examined were between 43-100% identical, 
suggesting that these are products of the same family 
of genes, whereas comparisons of sequence identities 
of vertebrate SCARB2 proteins with human SCARB1 
and CD36 proteins exhibited lower levels of sequence 
identities (30-36%), indicating that these are members 
of distinct CD36-like gene families (Table 1). The 
amino acid sequences for mammalian SCARB2 con-
tained 478 residues while chicken (Gallus gallus), liz-
ard (Anolis carolensis), frog (Xenopus tropicalis) and 
zebrafish (Danio rerio) SCARB2 contained 481, 482, 
483 and 474 amino acids, respectively (Table 1; Figure 
1). 
Previous studies have reported several key 
regions and residues for human and mouse SCARB2 
proteins (human SCARB2 amino acid residues were 
identified in each case). These included cytoplasmic N
-terminal and C-terminal residues, residues 2-6 and 
457-478, and N-terminal and C-terminal transmem-
brane helical regions: residues 7-30 and 432-456 
(Fujita et al. 1992, Tabuchi et al. 1997). These motifs 
underwent significant changes in amino acid sequence 
but retained the predicted cytoplasmic and transmem-
brane properties in each case (Figure 1). These 
changes are in contrast to the N-terminal transmem-
brane sequences for vertebrate SCARB1 and CD36 
sequences, for which several glycine residues were 
predominantly conserved, especially for CD36 Gly12, 
Gly16 and Gly24/Gly25 residues and for SCARB1 key 
N-terminal glycine residues (Gly15/Gly18/Gly25) 
(Holmes & Cox 2012), which form a dimerization mo-
tif in the N-terminal transmembrane domain and par-
ticipate in forming SCARB1 oligomers (Gaidukov et 
al. 2011). There were no SCARB2 N-terminal trans-
membrane glycine residues conserved for the verte-
brate sequences examined, although Gly10 was pre-
dominantly conserved with a Gly/Ala substitution ob-
served for the frog SCARB2 sequence (Figure 1). A 
conserved glycine residue was observed for the verte-
brate C-terminal transmembrane sequences (human 
SCARB2 Gly449) (Figure 1); however the role of this 
residue has not been investigated. 
 
Comparative Sequences for Vertebrate SCARB2 N-
Glycosylation Sites 
Ten N-glycosylation sites for human SCARB2 have 
been previously identified for this protein (Figure 1; 
Table 2) (Lewandrowski et al. 2005), whereas eleven 
such sites have been reported for mouse SCARB2 
(Tabuchi et al. 1997). All of these sites were predomi-
nantly retained among the 16 vertebrate SCARB2 se-
quences examined. Given the sequence conservation 
observed for these residues among the vertebrate 
SCARB2 sequences examined, it is apparent that they 
are essential for the function of vertebrate SCARB2 as 
a glycoprotein. The multiple N-glycosylation sites ob-
served for vertebrate SCARB2 sequences were consis-
tent with a major role for N-proteoglycan residues ex-
posed on the external membrane surface of lysosomes 
in the performance of SCARB2 functions in binding 
various lipid molecules, and in their reported functions 
in maintaining the organization of lysosomal and en-
dosomal membranes (Gamp et al. 2003; Kuronita et al. 
2002). This is also supported by recent animal model 
studies, which demonstrated a key role for N-
glycosylation in the recruitment of a related integrated 
membrane CD36-like family member (CD36) into car-
diac membranes (Lauzier et al. 2011).  
 
Vertebrate SCARB2 Cysteine Residues  
Four conserved external lysosomal membrane verte-
brate SCARB2 cysteine residues were observed: 
Cys274, Cys312, Cys318 and Cys329, which corre-
sponded to four of six previously identified disulfide 
forming cysteine residues for bovine CD36  
(Rasmussen et al. 1998). In contrast, ten cysteine resi-
dues of the vertebrate CD36 sequences were con-
served, including two within each of the N- (Cys3 and 
Cys7) and C-terminal (Cys464 and Cys466) cytoplas-
mic sequences, and six within the vertebrate exoplas-
mic sequences (Cys243; Cys272; Cys311; Cys313; 
Cys322; and Cys333) (Holmes & Cox 2012). The 
CD36 N- and C-terminal conserved cytoplasmic cys-
teine residues have been shown to be palmitoylated 
(Tao et al. 1996), which may contribute to protein-
protein interactions, protein trafficking and membrane 
localization (Salaun et al. 2010). These conserved cys-
teines are lacking in the vertebrate SCARB2 sequences 
(Figure 1), which suggests that S-palmitoyl cysteine 
residues do not play a role for this lysosomal mem-
brane protein. Vertebrate SCARB1 exoplasmic se-
quences also contained only four conserved cysteine 
residues forming disulfide bridges (Cys281; Cys321; 
Cys323; and Cys334) (Holmes & Cox 2012) although 
another conserved SCARB1 cysteine (not observed in 
the CD36 and SCARB2 sequences) (human SCARB1 
Cys384) serves a major role in lipid transfer activity 
(Papale et al. 2011, Yua et al. 2011) (Figure 2). 
 
SCARB2 C-terminal Lysosomal Targeting Se-
quences 
The targeting of SCARB2 to lysosomes has been pre-
viously shown to result from a Leu-Ile dipeptide motif 
104   Journal of Molecular Biochemistry, 2012 
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in the Leu475-Ile476-Arg477-Thr478 C-terminal cyto-
plasmic sequence (Ogata & Fukuda 1994, Tabuchi et 
al. 1997). The deletion of the nine amino acids closer 
to the SCARB2 C-terminal transmembrane domain 
also abolished this lysosomal location suggesting that 
an extended cytoplasmic tail for this protein is required 
for this function. Figure 1 shows a comparison of ver-
tebrate SCARB2 C-terminal sequences, with the 7 se-
quences examined showing a Leu-Ile or a Leu-Leu 
(zebrafish SCARB2) C-terminal sequence in each 
case, which is consistent with a proposal for a dileu-
cine (or leucine-isoleucine) lysosomal sorting motifs 
reported for the COOH tails of SCARB2 (Sandoval et 
al. 2000) and GLUT4 (insulin-regulatable glucose 
transporter) (James et al. 1989). Tabuchi and cowork-
ers (2000; 2002) have also reported that two acidic 
amino acids (Asp470-Glu471) in the COOH-terminal 
SCARB2 sequence play important roles in regulating 
the movement of this protein within the endocytic 
pathway. A comparison of vertebrate SCARB2 C-
terminal sequences supports this hypothesis with 
acidic amino acids being predominantly conserved for 
these positions, with the exception of zebrafish 
SCARB2, which has an apparent human 470Asp
zebrafish 466Ala substitution, but with an additional 
acidic amino acid (469Glu) further down the C-
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TSP1-A TSP1-B
TSP1-B TSP1-C
Figure 2. Amino Acid Sequence Alignments for Rat (Ra) SCARB2 (SCA2), SCARB1 (SCA1) and CD36 Sequences with 
Lancelet (La), Sea Squirt (Ss) and Fruit Fly (DmEMP1) CD-36 Like Sequences. See Table 1 for sources of rat SCARB2, 
SCARB1 and CD36 sequences as well as other CD36-like sequences; * shows identical residues for CD36-like subunits; : 
similar alternate residues; . dissimilar alternate residues; predicted cytoplasmic residues are shown in red; predicted transmem-
brane residues are shown in blue; N-glycosylated and potential N-glycosylated Asn sites are highlighted in green; free-SH Cys 
involved in lipid transfer for rat SCARB1 is highlighted in pink; predicted disulfide bond Cys residues are highlighted in cyan 
blue; predicted α-helices for vertebrate CD36-like sequences are highlighted in yellow and numbered in sequence from the start 
of the predicted exoplasmic domain; predicted β-sheets are highlighted in grey and also numbered in sequence; bold underlined 
font shows residues corresponding to known or predicted exon start sites; exon numbers are shown; AKL refers to final three C
-terminal residues for rat SCARB1 which bind a PDZ domain-containing protein (PDZK1); transmembrane conserved glycines 
are shown as G; TSP1-A, TSP1-B and TSP1-C represent motifs identified by Crombie & Silverstein 1998. 
terminal cytoplasmic tail (Figure 1). The intracellular 
trafficking of lysosomal membrane proteins has been 
extensively investigated in recent years, and these 
studies have shown that sorting from the Golgi or the 
plasma membrane into the endosomes and lysosomes 
represents one pathway which is mediated by short 
COOH-terminal cytoplasmic sequences (Hunziker & 
Geuze 1996). The dileucine cytoplasmic signal is one 
such pathway, however others also serve to target ly-
sosomal proteins, such as cholesterol ester lipase 
(LIPA) which contains a C-terminal Arg-Lys dipeptide 
sequence (Sleat et al. 2006) and the C-terminal tyro-
sine based lysosomal targeting signal reported for ly-
sosome-associated membrane glycoprotein-1 (LAMP-
1) (Akasaki et al. 2010, Höning et al. 1996). 
 
Predicted Secondary Structures for Vertebrate 
SCARB2 
Predicted secondary structures for vertebrate SCARB2 
sequences were examined (Figure 1), particularly for 
the sequences external to the lysosomal membrane 
(residues 28-433 for rat SCARB2) (Figure 2). α-Helix 
and β-sheet structures were similar in each case, with a 
α-helix extending beyond the N-terminal and C-
terminal transmembrane regions in each case: α1 and 
α6. A consistent sequence of predicted secondary 
structure was also observed for each of the vertebrate 
SCARB2 sequences:  N-terminal cytoplasmic se-
quence--N-terminal transmembrane sequence--α1--β1-
-α2--β2--β3--β4--β5--α3--β6--α4--α5--β7--β8--β9--β10
--β11--β12--β13--β14--α6--C-terminal trans-membrane 
sequence--C-terminal cytoplasmic sequence. Further 
description of the secondary and tertiary structures for 
SCARB2 must await the three dimensional structure of 
this protein, particularly for the external lysosomal 
membrane region which directly binds lipids and con-
tributes towards the organization and maintenance of 
the lysosomal membranes (Gamp et al. 2003; Kuronita 
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Figure 3. Gene Structures and Major Transcripts for the Human, Mouse and Rat SCARB2 Genes. Derived from the AceView 
website http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/; 31 mature isoforms are shown with capped 5’- and 3’- ends for 
the predicted mRNA sequences; NM refers to the NCBI reference sequence; exons are in pink; the directions for transcription 
are shown as 5’  3’; black squares show predicted CpG island sites at or near the 5’untranslated regions of the genes; the 
symbol ⌃ shows 10 predicted microRNA binding sites observed at or near the SCARB2 3’untranslated regions; sizes of mRNA 
sequences are shown in kilobases (kb); predicted transcription factor binding sites (TFBS) for human SCARB2 are shown: 
PPARA- peroxisome proliferator-activated receptor-α ; ATF-activation transcription factor; IRF7-interferon regulatory factor; 
HAND1-heart- and neural crest derivatives-expressed protein system; EVI1-ecotropic viral integration site; NKX 2.2-
et al. 2002). 
 
Conserved Proline and Glycine Residues within the 
SCARB2 External Lysosomal Membrane Domain 
Figure 1S (see supplementary data) shows the align-
ment of 7 vertebrate SCARB2 amino acid sequences 
for the external lysosomal membrane domain with col-
ors depicting the properties of individual amino acids 
and conservation observed for some of these protein 
sequences. In addition to the key vertebrate SCARB2 
amino acids detailed previously, others were also con-
served, including 16 proline residues. Prolines play a 
major role in protein folding and protein-protein inter-
actions, involving the cyclic pyrrolidine amino acid 
side chain, which may introduce turns (or kinks) in the 
polypeptide chain as well as having destabilizing ef-
fects on α-helix and β-strand conformations 
(MacArthur & Thornton 1991). In addition, the pres-
ence of sequential prolines within a protein sequence 
may confer further restriction in folding conformation 
and create a distinctive structure, such as that reported 
for the mammalian Na+/H+ exchanger, which plays a 
major role in cation transport (Kreiger et al. 2005). 
Sequential prolines (P1 and P2: Pro57-Pro58) were 
conserved for 6 of 7 vertebrate SCARB2 sequences 
examined, which may confer a distinctive conforma-
tion in this region supporting the lipid receptor func-
tions for this protein. For three of the vertebrate 
SCARB2 sequences examined, four sequential proline 
residues were observed (chicken, frog and zebrafish: 
Pro57-Pro58-Pro59-Pro60) which may contribute fur-
ther to the distinctive folding conformation in this re-
gion. Regions of water exposed proteins with high lev-
els of proline residues are often sites for protein-
protein interactions (Kay et al. 2000) and these resi-
dues may significantly contribute to the binding of lip-
ids by the external lysosomal membrane region of 
SCARB2. Similar results have been recently reported 
for vertebrate SCARB1 and CD36 exoplasmic regions, 
however 30 and 17 conserved proline residues were 
observed, respectively in these proteins (Holmes & 
Cox 2012). 
 Figure 1S (see supplementary data) also shows 
conservation of 20 glycine residues for these vertebrate 
SCARB2 external domains of lysosomal membranes, 
which due to their small size, may be essential for 
static turns, bends or close packing in the domain, or 
required for conformational dynamics during lipid re-
ceptor on-off switching, as in the case of the aspartate 
receptor protein (Coleman et al. 2005). Both proline 
and glycine residues are frequently found in turn and 
loop structures of proteins, and usually influence short 
loop formation within proteins containing between 2 
and 10 amino acids (Kreiger et al. 2005). Evidence for 
these short loop structures within vertebrate SCARB2 
external lysosomal membrane sequences was evident 
from the predicted secondary structures for vertebrate 
SCARB2 (Figure 1), with proline and/or glycine resi-
dues found at the start or end of the following struc-
tures: β1 (Pro57; Pro58; Pro60), α2 (Pro72), β2 (Gly78
-Pro81), β3 (Gly87/Pro88), β4 (Gly106), α3 (Pro139), 
α5 (Gly179), β7 (Gly211; Gly218), β8 (Gly233), β11 
(Gly211) and β12 (Pro371) (Figure 1). 
 
Alignments of Rat SCARB2, SCARB1 and CD36 
with other CD36 Sequences 
  The amino acid sequences for rat SCARB2, 
SCARB1 and CD36 (see Table 1) are aligned in Figure 
2. The sequences were 30-33% identical and showed 
similarities in several key features and residues, in-
cluding cytoplasmic N-terminal and C-terminal resi-
dues; N-terminal and C-terminal trans-membrane heli-
cal regions; disulfide bond forming residues, previ-
ously identified for bovine CD36: Cys243-Cys311, 
Cys272-Cys333 and Cys313-Cys322 (Rasmussen et 
al. 1998); several predicted N-glycosylation sites for 
rat SCARB2 (11 sites) (Table 2), rat SCARB1 (10 
sites) and CD36 (9 sites) (Holmes & Cox 2012), of 
which only one was shared between these sequences 
(N-glycosylation site 10) (Table 2); similar throm-
bospondin-1 binding sites (designated as TSP1-A, 
TSP1-B and TSP1-C) previously reported for 
SCARB2, SCARB2 and CD36 (Crombie & Silverstein 
1998) and similar predicted secondary structures previ-
ously identified for SCARB1 and CD36 (Holmes & 
Cox 2012) (Figure 1). Sequence comparisons for the 
TSP1 binding sites confirmed the presence of a protein 
kinase C consensus phosphorylation site (Crombie & 
Silverstein 1998) within the TSP1-A site (GPYTYR) 
for rat SCARB2, CD36 and SCARB1 (but with a sub-
stitution at one site: GPYVYR). The current studies 
demonstrated other common features of these sites; 
namely the predicted β-sheet secondary structures for 
TSP1-A (β2) and TSP1-B (β3), the absence of pre-
dicted secondary structure for TSP1-C (located be-
tween β5 and β6) and the predicted N-glycosylation 
sites observed for TSP1-B. The Cys384 residue, for 
which the free-SH group plays a major role in 
SCARB1-mediated lipid transport (Yua et al. 2011), 
was unique to SCARB1, being replaced by other resi-
dues for the corresponding SCARB2 and CD36 pro-
teins (Gly379 and Phe383, respectively). N-terminal 
transmembrane glycine residues, which play a role in 
the formation of SCARB1 oligomers (Gaidukov et al. 
2011), were also observed for the rat CD36 sequence, 
although twin-glycines (Gly23-Gly24) were observed 
for the vertebrate CD36 sequences (Holmes & Cox 
2012). In contrast, only one of these glycines (Gly10) 
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was observed for the rat SCARB2 N-terminal trans-
membrane sequence. These results suggest that rat 
SCARB2, SCARB1 and CD36 proteins share several 
important properties, features and conserved residues, 
including being membrane-bound with cytoplasmic 
and transmembrane regions, N-glycosylated at specific 
sites and have similar secondary structures but each is 
sufficiently different to serve distinct functions exter-
nal to the respective membrane surfaces. 
 Alignments were also prepared for the pre-
dicted lancelet (Branchiostoma floridae) and sea squirt 
(Ciona intestinalis) CD36-like sequences (Table 1) 
and a major epithelial membrane protein (EMP) from 
the fruit fly (Drosophila melanogaster ) 
(FBpp0072309) (Nichols & Vogt 2008) with the rat 
SCARB2, SCARB1 and CD36 sequences (Figure 2). 
The lancelet, sea squirt and fruit fly sequences exam-
ined shared many features with the CD36-like rat se-
quences, including the N- and C-terminal cytoplasmic 
and transmembrane sequences, similarities in predicted 
secondary structures, positional identities for five con-
served cysteine residues (indicating conservation of at 
least 2 disulfide bridges for these proteins), predicted 
N-glycosylation sites (including one which is shared 
across all 6 CD-like sequences; site 10 in Table 2) and 
transmembrane glycine residues, which were observed 
in both the N- and C-terminal sequences, although 
with only a single glycine residue for the human 
SCARB2 sequence. 
 
Gene Locations and Exonic Structures for Verte-
brate SCARB2 Genes 
Table 1 summarizes the predicted locations for verte-
brate SCARB2 genes based upon BLAT interrogations 
of several vertebrate genomes using the reported hu-
man and mouse SCARB2 sequences (Fujita et al. 
1992, Tabuchi et al. 1997) and the predicted sequences 
for other vertebrate and fruit fly CD36-like genes de-
rived from the UC Santa Cruz genome browser (Kent 
et al. 2003). The predicted vertebrate SCARB2 genes 
were transcribed on either the positive strand (e.g. 
chimpanzee, rhesus monkey, marmoset, rat, chicken, 
lizard and zebrafish genomes) or the negative strand 
(e.g. human, orangutan, mouse, cow, pig, opossum, 
chicken and frog genomes). Figure 1 summarizes the 
predicted exonic start sites for human, mouse, cow, 
chicken, lizard, frog and zebrafish SCARB2 genes with 
each having 12 coding exons, in identical or similar 
positions to those reported for the human SCARB2 
gene (Kent et al. 2003). 
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Figure 4. Comparative Tissue Expression for Human and Mouse SCARB2 Genes. Expression ‘heat maps’ (GNF Expression 
Atlas 2 data) (http://biogps.gnf.org) (Su et al, 2004) were examined for comparative gene expression levels among human and 
mouse tissues for SCARB2 genes showing high (red); intermediate (black); and low (green) expression levels. Derived from 
human and mouse genome browsers (http://genome.ucsc.edu) (Kent et al. 2003). 
Figure 3 shows the predicted structures for the 
major human, mouse and rat SCARB2/Scarb2 tran-
scripts (Thierry-Mieg & Thierry-Mieg 2006). The tran-
scripts were ~2kbs in length with 12 exons present for 
the mRNA transcripts and in each case, a non-coding 
5’-untranslated sequence and an extended 3’-
untranslated region (UTR) were observed.  The human 
SCARB2 genome sequence contained several predicted 
transcription factor binding sites (TFBS), including 
PPARA (peroxisome proliferator-activated receptor-
α), which plays a major role in kidney proximal tubule 
development and maintenance (Kamijo et al. 2002) 
where SCARB2 is highly expressed (Berkovic et al. 
2008, Desmond et al. 2011); NRSF (neuron-restrictive 
silencing factor), which functions as a neuronal cell 
repressor (Kim et al. 2004); ATF (activating transcrip-
tion factor 1) which mediates heme oxygenase induc-
tion by heme and drives macrophage adaptation to in-
traplaque hemorrhage during atherosclerosis (Boyle et 
al. 2012); IRF7 (interferon regulatory factor-7) which 
is critical for the regulation of inflammatory responses 
in the central nervous system (Salem et al. 2011); 
HAND1 (heart- and neural crest derivatives-expressed 
protein system) which drives ongoing expression of 
cardiac-specific genes (Riley et al. 1998); EVI1 
(ecotropic viral integration site), which is a complex 
transcription factor with multiple functions 
(Buonamici et al. 2003) and NKX22 (homeobox pro-
tein Nkx-2.2) which contributes to the expression of 
genes that play a role in axonal guidance (Holz et al. 
2010). 
 Figure 3 also reports the presence of a CpG is-
land within the promoter region of the human, mouse 
and rat SCARB2 genes (CpG100, CpG69 and CpG60, 
respectively). CpG islands were also observed within 
the promoter regions of other vertebrate SCARB2 
genes, including marmoset (CpG106), pig (CpG71) 
and lizard (CpG420) (data not shown). CpG islands are 
typically found within the gene promoter for house-
keeping genes (Saxanov et al. 2006). Elango & Yi 
(2011) have also proposed that larger CpG islands are 
associated with gene promoters showing a broad range 
of gene expressions and contain more RNA poly-
merase II binding sites than other promoters. Conse-
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Figure 5: Phylogenetic Tree of Vertebrate SCARB2 Amino Acid Sequences with Human, Mouse, Chicken and Zebrafish 
SCARB1 and CD36 Sequences. The tree is labeled with the SCARB-like name and the name of the animal and is ‘rooted’ with 
the lancelet CD36 sequence. Note the 3 major clusters corresponding to the SCARB2, SCARB1 and CD36 gene families. A ge-
netic distance scale is shown. The number of times a clade (sequences common to a node or branch) occurred in the bootstrap 
replicates are shown. Only replicate values of 95 or more, which are highly significant are shown with 100 bootstrap replicates 
performed in each case.  
quently, the presence of CpG100 and the transcription 
factor binding sites observed within the SCARB2 gene 
may contribute significantly to the broad tissue expres-
sion observed for SCARB2 transcripts. The human 
SCARB2 transcript also contained an extended 3’-
noncoding segment with ten predicted miRNA binding 
sites (miR-340, 203, 10, 182, 590, 876, 141, 542, 219 
and 494), which is well in excess of the usual number 
of such sites. miRNAs have been reported to function 
as post-transcriptional regulators that bind to comple-
mentary sequences on target messenger RNA tran-
scripts (mRNAs), which result in translational repres-
sion or target degradation and gene silencing (Bartel 
2009). 
 
Comparative Human and Mouse SCARB2 Tissue 
Expression 
Figure 4 presents ‘heat maps’ showing comparative 
gene expression for various human and mouse tissues 
obtained from GNF Expression Atlas Data using the 
U133A and GNF1H (human) and GNF1M (mouse) 
chips (http://genome.ucsc.edu; http://biogps.gnf.org) 
(Su et al. 2004). These data support a broad and high 
level of tissue expression for human and mouse 
SCARB2, particularly for adipose tissue, cardiac myo-
cytes, skeletal muscle and liver which is consistent 
with previous reports for these genes (Calvo et al. 
1995, Fujita et al. 1992, Ogata et al. 1994, Tabuchi et 
al. 1997). Much lower levels of mouse Scarb2 gene 
expression were observed in oocytes and during early 
embryonic development. Overall, however, human and 
mouse SCARB2 tissue expression levels were 2-4 
times higher than the average level of gene expression, 
which supports the key role played by this protein in 
lysosomal and endosomal membranes of the body. 
 
Phylogeny of vertebrate SCARB2 and related 
CD36-like sequences   
A phylogenetic tree (Figure 5) was calculated by the 
progressive alignment of 17 vertebrate SCARB2 
amino acid sequences with human, mouse, chicken and 
zebrafish SCARB1 and CD36 sequences ‘rooted’ with 
the lancelet (Branchiostoma floridae) CD36 sequence 
(see Table 1). The phylogram showed clustering of the 
SCARB2 sequences into groups which were consistent 
with their evolutionary relatedness as well as groups 
for human, mouse, chicken and zebrafish SCARB1 
and CD36 sequences, which were distinct from the 
lancelet CD36 sequence. These groups were signifi-
cantly different from each other (with bootstrap values 
of ~ 100/100). It is apparent from this study of verte-
brate CD-like genes and proteins that this is an ancient 
protein for which a proposed common ancestor for the 
CD36, SCARB1 and SCARB2 genes may have pre-
dated the appearance of fish  > 500 million years ago 
(Donohue & Benton 2007). In parallel with the evolu-
tion of SCARB2 and other CD36-like proteins 
(SCARB1 and CD36), thrombospondins (TSPs) are 
also undergoing evolutionary changes in their struc-
tures and functions (Bentley & Adams 2010), with 
gene duplication events proposed at the origin of deu-
terostomes. 
 
Conclusions 
 
The results of the present study indicate that vertebrate 
SCARB2 genes and encoded proteins represent a dis-
tinct gene and protein family of CD36-like proteins 
which share key conserved sequences that have been 
reported for other CD36-like proteins (SCARB1 and 
CD36) previously studied (Acton et al. 1996, Bultel-
Brienne et al. 2002, Connelly et al. 2004, Fujita et al. 
1992, Holmes & Cox 2012, Kent et al. 2011, Kuronita 
et al. 2002, Lin et al. 2012, Marsche et al. 2003, Ogata  
& Fukuda 1994, Tabuchi et al. 1997). SCARB2 has a 
unique property among these proteins in serving major 
roles within endosomal and lysosomal membranes of 
various cells and tissues of the body. SCARB2 is en-
coded by a single gene among the vertebrate genomes 
studied and is highly expressed in human and mouse 
tissues, particularly in adipose tissue, cardiac myo-
cytes, skeletal muscle and liver, and usually contained 
12 coding exons. Predicted secondary structures for 
vertebrate CD36 proteins showed strong similarities 
with other CD36-like proteins, SCARB1 and CD36. 
Three major structural domains were apparent for ver-
tebrate SCARB2, including the N-terminal and C-
terminal cytoplasmic domains, the N-terminal and C-
terminal transmembrane domains, the external ly-
sosomal membrane domain, two disulfide bridges and 
several N-glycosylation sites for glycan binding, which 
are apparently essential for membrane recruitment. 
Phylogenetic studies using 17 vertebrate SCARB2 se-
quences with human, mouse, chicken and zebrafish 
SCARB1 and CD36 sequences indicated that the 
CD36 gene has appeared early in evolution, prior to 
the appearance of bony fish more that 500 million 
years ago, and has undergone at least two gene dupli-
cation events. 
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